Annual report pursuant to Section 13 and 15(d)

Consolidated Statements of Operations

v3.24.1
Consolidated Statements of Operations - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Operating expenses    
Research and development $ 6,131 $ 2,698
Research and development - licenses acquired 4,230 0
General and administrative 4,179 5,345
Loss from operations (14,540) (8,043)
Interest income (126) (20)
Financing costs – warrant liabilities (332) (1,160)
Change in fair value of warrant liabilities 4,258 5,580
Net loss (10,488) (3,603)
Net loss attributable to non-controlling interest (111) (51)
Net loss attributable to common stockholders $ (10,377) $ (3,552)
Net loss per common share attributable to common stockholders, basic and diluted (in dollars per share) $ (0.98) $ (1.63)
Weighted average number of common shares outstanding, basic and diluted (in shares) 10,591,636 2,185,159